FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | | |
|--------------------------|--------|--|--|--|--|--|--|--|--|
| OMB Number: 3235-02 | | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response | 9: 0.5 | | | | | | | | |

| | Check this box if no longer subject |
|--------|-------------------------------------|
| \neg | to Section 16. Form 4 or Form 5 |
| _ | obligations may continue. See |
| | Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* | | | | | 2. Issuer Name and Ticker or Trading Symbol Sotera Health Co [SHC] | | | | | | | | | | heck all ap X Dire | nship of Reportii I applicable) Director | | 10% O | wner | |
|---|--|----------|---------|---------------------------------------|--|---|----------------------|--------------------------------|---------------------|---|--|-------|-------------------------------------|---|--|--|--|--|---------|--|
| (Last) | (F | rst) (N | Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 05/26/2023 | | | | | | | | | | Offic belo | er (give title w) | | Other (below) | specify | |
| C/O SOTERA HEALTH COMPANY 9100 SOUTH HILLS BLVD., SUITE 300 | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | |
| (Street) BROAD HEIGHT | DADVIEW OH 44147 | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | Form filed by More than One Reporting Person | | | | | | |
| (City) | (S | tate) (Z | Zip) | - | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | ended to | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/ | | | | Execution Date, | | | | | | ies Acquired (A) Of (D) (Instr. 3, 4 | | | nd Secur Benef Owne Follow | icially d ving | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | | | | Code | v | Amount | | A) or D) | Price | | orted saction(s) r. 3 and 4) | | | | |
| Common Stock, \$0.01 par value per share (Common Stock) 05/26/20 | | | | | .023 | | | A | | 15,712 ⁽¹ | 2 ⁽¹⁾ A | | \$0.0 | 00 92 | 92,485 ⁽²⁾ | | D | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | Derivative Conversion Date Security or Exercise (Month/Day/Year) if any | | | | Transaction Code (Instr. 8) De Se Ac (A Dii | | osed) r. 3, 4 | 6. Date Expirati (Month/ | on Da | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and | | f g nd 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | e s lly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercisable | | Expiration Date | Title | of | nber ares | | | | | | |

Explanation of Responses:

- 1. These securities consist of 15,712 Restricted Stock Units ("RSUs") that were granted on May 26, 2023, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date.
- 2. Consists of 15,712 RSUs and 76,773 shares of Common Stock, including 62,864 shares of vested Common Stock and 13,909 shares of unvested Common Stock. The unvested shares of Common Stock will vest on a daily basis pro rata through May 27, 2025.

Remarks:

The Power of Attorney for Ms. Klee is filed as an exhibit to the Form 3 filed with the Securities and Exchange Commission on November 20, 2020, which is hereby incorporated by reference.

/s/ Jessica L.M.H. Epp, Attorney-in-Fact 05/31/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.